CT/NG检测市场－全球产业规模、份额、趋势、机会及预测（按产品、检测类型、技术、最终用户、地区和竞争格局划分，2021-2031年）

全球 CT/NG 影像市场预计将从 2025 年的 18.7 亿美元成长到 2031 年的 31.1 亿美元，复合年增长率为 8.84%。

该市场主要包括采用核酸扩增技术、专门用于定性检测淋病奈瑟菌（Neisseria gonorrhoeae）和披衣菌感染（Chlamydia trachomatis）病原体的诊断设备系统和检测方法。市场成长的主要驱动因素是这些性行为感染传染病在全球范围内的发病率不断上升以及政府主导的筛检计画的扩展。此外，在非传统医疗机构中采用就地检验方法也加速了快速诊断工具的普及，有助于更快地治疗并更好地管理疾病。

阻碍市场扩张的主要挑战之一是这些疾病的社会污名化和无症状感染的特点，这使得许多人不愿意接受自愿检测。这一障碍限制了有效病例的发现，并降低​​了关键人群获得诊断产品的机会。美国国家性传染病主任联盟强调了这种持续存在的疾病负担，该联盟报告称，到2024年，美国将记录超过220万例披衣菌感染、淋病和梅毒病例。如此庞大的性行为感染人数表明，对健全的诊断检测基础设施的需求将持续存在。

市场驱动因素

面向消费者的家用自采集试剂盒的普及显着扩大了市场进入，避免了传统诊所检测带来的社会污名和后勤障碍。这一趋势促进了诊断的广泛应用，使个人能够在私密环境中进行高精度检测，这对于发现无症状感染疾病至关重要。製造商正不断获得监管机构对其面向消费者的先进分子平台的核准，从而弥合了专业检查室的精准度与消费者使用便利性之间的差距。据Visby Medical公司称，在2025年3月的监管成就公告中，美国食品药物管理局（FDA）批准了其女性性健康检测套组作为全新医疗设备认证，使其成为首个核准用于检测披衣菌感染和淋病的商用家用PCR诊断设备。

同时，向高灵敏度核酸增幅检查(NAAT) 的技术转型以及自动化高通量系统的整合正在简化临床工作流程，以满足持续成长的检测需求。实验室优先选择能够快速出结果并整合检测菜单的平台，以便在保持高特异性的同时高效处理大量检体。这种营运效率的提升也体现在投资分子平台的主要产业参与者的财务表现。根据罗氏公司于 2025 年 1 月发布的《2024 年年度报告》，其诊断部门的销售额达到 143 亿瑞士法郎，核心业务成长 8%，主要得益于对免疫诊断和分子解决方案需求的成长。这种诊断能力对于公共卫生监测仍然至关重要。根据英国卫生安全局统计，上年度2025 年，英格兰就记录了 71,802总合淋病诊断病例，凸显了建立健全的监测系统的必要性。

市场挑战

与性行为感染传染病相关的社会污名，加上披衣菌感染披衣菌和淋病奈瑟菌感染通常无症状，对诊断市场的发展构成了重大障碍。患者在没有出现任何身体症状时往往不愿就医，而对社会评价的担忧进一步抑制了自愿筛检。这种犹豫直接减少了患者主导咨询医疗保健提供者的次数，并降低了诊断检测套组和设备的整体使用率。因此，製造商面临一个有限的市场，该市场主要以反应性检测为主，而非预防性检测，这大大限制了检测套组的潜在消耗量。

这些持续存在的未被发现的感染病例凸显了筛检对市场的影响。病原体的无症状传播导致大量检测机会的错失，限制了诊断服务提供者的收入来源，并减缓了关键人口的市场渗透率。例如，美国县市卫生专员协会预测，到2024年，先天性梅毒病例将增加2%，达到约4,000例，这反映了这些障碍所蕴含的潜在检测价值。这项统计数据表明，未能及时发现无症状感染是一个重大挑战，并突显了这些疾病的潜伏期如何成为全球检测市场扩张的根本限制因素。

市场趋势

市场正迅速转向能够同时检测披衣菌感染披衣菌、淋病奈瑟菌以及常见共感染疾病（如霉浆菌支原体和阴道毛滴虫）的多综合征检测组合。这一转变的驱动力源于临床需求，即在一次诊疗中区分重迭的病原体，突破单靶点检测的局限性，旨在改善抗生素管理。领先的综合征检测组合供应商的强劲商业性表现也为这一市场趋势提供了有力支撑。根据生物梅里埃公司于2025年3月发布的2024财年财务报告，该公司非呼吸道生物检测组合的销售额成长了17%，显示在临床工作流程中，全面感染疾病分析的应用正在加速。

随着综合征检测组合的兴起，分子诊断迁移到分散式临床机构（例如急诊中心和门诊诊所）的趋势也日益明显。与居家检测和集中式检查室处理不同，此趋势着重于在护理点实施快速PCR检测，旨在透过实施即时治疗通讯协定来最大限度地减少失访患者。随着医疗网路优先考虑更贴近病患的就医途径，这种分散式基础设施的实体规模正在显着扩大。根据丹纳赫公司2025年1月发布的“2024年第四季度财报会议纪要”，Sepede分子诊断系统的全球装机量实现了接近两位数的增长，突破6万台。这项里程碑式的成就主要得益于传统医院检查室以外的其他医疗机构的快速部署。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章：全球CT/NG检查市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 依产品分类（检测及试剂盒、仪器/分析设备）
  • 依检测类型（实验室检测、即时检测）
  • 透过科技（免疫诊断、恒温核酸增幅技术、聚合酵素链锁反应）
  • 依最终使用者（临床检查室、医院/诊所、其他）划分
  • 按地区
  • 按公司（2025 年）
• 市场地图

第六章：北美CT/NG检查市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

7.欧洲CT/NG检查市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

8.亚太CT/NG检查市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

9. 中东和非洲CT/NG检查市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章：南美洲CT/NG检查市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章：全球CT/NG侦测市场：SWOT分析

第十四章 波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• F. Hoffmann-La Roche Ltd.
• Hologic, Inc.
• Thermo Fisher Scientific Inc.
• Abbott Laboratories Inc.
• QIAGEN NV
• PerkinElmer Inc.
• Bio-Rad Laboratories, Inc.
• Siemens Healthineers AG
• Danaher Corporation
• Becton, Dickinson, and Company

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global CT and NG Testing Market is projected to expand from USD 1.87 Billion in 2025 to USD 3.11 Billion by 2031, reflecting a compound annual growth rate of 8.84%. This market encompasses diagnostic instrument systems and assays specifically engineered for the qualitative detection of Neisseria gonorrhoeae and Chlamydia trachomatis pathogens, predominantly employing nucleic acid amplification technologies. The market's trajectory is primarily propelled by the rising global incidence of these sexually transmitted infections alongside the broadening enforcement of government-led screening programs. Additionally, the incorporation of point-of-care testing methods within non-traditional healthcare environments is hastening the uptake of rapid diagnostic tools, thereby enabling prompter treatment and better disease management.

One significant challenge impeding market expansion is the social stigma and asymptomatic nature of these diseases, which frequently discourages individuals from seeking voluntary testing. This barrier limits effective case finding and reduces the utilization of diagnostic products in key demographics. The persistent disease burden is highlighted by the National Coalition of STD Directors, which reported that in 2024, more than 2.2 million cases of chlamydia, gonorrhea, and syphilis were recorded in the United States. This substantial volume of infections indicates a sustained demand for robust diagnostic testing infrastructure.

Market Driver

The proliferation of direct-to-consumer and at-home self-collection kits is significantly expanding market access by circumventing the social stigma and logistical barriers associated with traditional clinic-based testing. This driver is democratizing diagnostic availability, allowing individuals to perform high-accuracy testing in private settings, which is crucial for capturing asymptomatic infections that might otherwise go undetected. Manufacturers are increasingly securing regulatory approvals for sophisticated molecular platforms designed for lay users, bridging the gap between professional lab accuracy and consumer convenience. According to Visby Medical, in a March 2025 announcement regarding regulatory achievements, the U.S. Food and Drug Administration granted De Novo authorization for their Women's Sexual Health Test, establishing it as the first PCR diagnostic device approved for over-the-counter home use for the detection of chlamydia and gonorrhea.

Simultaneously, a technological shift toward high-sensitivity Nucleic Acid Amplification Tests and the integration of automated high-throughput systems are streamlining clinical workflows to meet sustained testing demand. Laboratories are prioritizing platforms that offer rapid turnaround times and consolidated menus to manage large sample volumes efficiently while maintaining high specificity. This operational efficiency is reflected in the financial performance of major industry players investing in molecular infrastructure. According to Roche, in the January 2025 'Annual Report 2024', the Diagnostics Division achieved sales of CHF 14.3 billion, with the base business growing by 8 percent largely due to increased demand for immunodiagnostic and molecular solutions. This diagnostic capacity remains critical for public health monitoring; according to the UK Health Security Agency, in 2025, a total of 71,802 diagnoses of gonorrhea were recorded for the preceding year in England alone, underscoring the continued necessity for robust surveillance systems.

Market Challenge

The social stigma associated with sexually transmitted infections, combined with the frequently asymptomatic presentation of Chlamydia trachomatis and Neisseria gonorrhoeae, creates a substantial barrier to the growth of the diagnostic market. When individuals do not experience physical symptoms, they often lack the motivation to seek medical attention, while fear of societal judgment further deters voluntary screening. This hesitation directly reduces the volume of patient-initiated visits to healthcare providers, thereby decreasing the overall utilization of diagnostic assays and instrumentation. Consequently, manufacturers face a restricted market where testing is primarily reactive rather than preventative, significantly suppressing the potential volume of assay consumption.

The persistence of these undetected infections highlights the market impact of this screening gap. Because these pathogens spread silently, a vast number of potential testing opportunities are missed, limiting revenue streams for diagnostic providers and stalling market penetration in key demographics. Illustrating the severity of missed detection due to these barriers, according to the National Association of County and City Health Officials, in 2024, congenital syphilis cases increased by 2% to nearly 4,000 cases. This statistic demonstrates the critical failure to capture asymptomatic infections in a timely manner, underscoring how the hidden nature of these diseases fundamentally curtails the expansion of the global testing market.

Market Trends

The market is increasingly shifting toward multiplex syndromic testing panels, which facilitate the simultaneous detection of Chlamydia trachomatis, Neisseria gonorrhoeae, and prevalent co-infections such as Mycoplasma genitalium and Trichomonas vaginalis. This transition is driven by the clinical necessity to distinguish between pathogens with overlapping symptoms in a single patient visit, moving beyond the limitations of single-target assays to improve antimicrobial stewardship. The operational momentum behind this approach is evidenced by the robust commercial performance of major syndromic panel providers. According to BioMerieux, in the March 2025 '2024 Financial Results', sales of the company's BIOFIRE non-respiratory panels increased by 17%, illustrating the accelerating uptake of comprehensive infectious disease profiling in clinical workflows.

Parallel to the rise of syndromic panels, there is a distinct transition of molecular diagnostics into decentralized clinical settings such as urgent care centers and outpatient clinics. Unlike at-home testing or central laboratory processing, this trend focuses on the professional administration of rapid PCR tests at the point of care to enable immediate treatment protocols, thereby minimizing the rate of patients lost to follow-up. The physical footprint of this decentralized infrastructure has widened significantly as healthcare networks prioritize near-patient accessibility. According to Danaher, in the January 2025 'Fourth Quarter 2024 Earnings Call Transcript', the global installed base of Cepheid molecular systems grew by high single digits to exceed 60,000 instruments, a milestone fueled largely by accelerated placements in alternate care sites beyond the traditional hospital laboratory.

Key Market Players

• F. Hoffmann-La Roche Ltd.
• Hologic, Inc.
• Thermo Fisher Scientific Inc.
• Abbott Laboratories Inc.
• QIAGEN N.V.
• PerkinElmer Inc.
• Bio-Rad Laboratories, Inc.
• Siemens Healthineers AG
• Danaher Corporation
• Becton, Dickinson, and Company

Report Scope

In this report, the Global CT and NG Testing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

CT and NG Testing Market, By Product

• Assays And Kits
• Instruments/Analyzers

CT and NG Testing Market, By Testing Type

• Lab Tests
• PoC Tests

CT and NG Testing Market, By Technology

• Immunodiagnostics
• Isothermal Nucleic Acid Amplification Technology
• Polymerase Chain Reaction

CT and NG Testing Market, By End User

• Clinical Laboratories
• Hospitals & Clinics
• Others

CT and NG Testing Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global CT and NG Testing Market.

Available Customizations:

Global CT and NG Testing Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global CT and NG Testing Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (Assays And Kits, Instruments/Analyzers)
  • 5.2.2. By Testing Type (Lab Tests, PoC Tests)
  • 5.2.3. By Technology (Immunodiagnostics, Isothermal Nucleic Acid Amplification Technology, Polymerase Chain Reaction)
  • 5.2.4. By End User (Clinical Laboratories, Hospitals & Clinics, Others)
  • 5.2.5. By Region
  • 5.2.6. By Company (2025)
• 5.3. Market Map

6. North America CT and NG Testing Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product
  • 6.2.2. By Testing Type
  • 6.2.3. By Technology
  • 6.2.4. By End User
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States CT and NG Testing Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Testing Type
      • 6.3.1.2.3. By Technology
      • 6.3.1.2.4. By End User
  • 6.3.2. Canada CT and NG Testing Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Testing Type
      • 6.3.2.2.3. By Technology
      • 6.3.2.2.4. By End User
  • 6.3.3. Mexico CT and NG Testing Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Testing Type
      • 6.3.3.2.3. By Technology
      • 6.3.3.2.4. By End User

7. Europe CT and NG Testing Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By Testing Type
  • 7.2.3. By Technology
  • 7.2.4. By End User
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany CT and NG Testing Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Testing Type
      • 7.3.1.2.3. By Technology
      • 7.3.1.2.4. By End User
  • 7.3.2. France CT and NG Testing Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Testing Type
      • 7.3.2.2.3. By Technology
      • 7.3.2.2.4. By End User
  • 7.3.3. United Kingdom CT and NG Testing Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Testing Type
      • 7.3.3.2.3. By Technology
      • 7.3.3.2.4. By End User
  • 7.3.4. Italy CT and NG Testing Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product
      • 7.3.4.2.2. By Testing Type
      • 7.3.4.2.3. By Technology
      • 7.3.4.2.4. By End User
  • 7.3.5. Spain CT and NG Testing Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product
      • 7.3.5.2.2. By Testing Type
      • 7.3.5.2.3. By Technology
      • 7.3.5.2.4. By End User

8. Asia Pacific CT and NG Testing Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By Testing Type
  • 8.2.3. By Technology
  • 8.2.4. By End User
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China CT and NG Testing Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Testing Type
      • 8.3.1.2.3. By Technology
      • 8.3.1.2.4. By End User
  • 8.3.2. India CT and NG Testing Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Testing Type
      • 8.3.2.2.3. By Technology
      • 8.3.2.2.4. By End User
  • 8.3.3. Japan CT and NG Testing Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Testing Type
      • 8.3.3.2.3. By Technology
      • 8.3.3.2.4. By End User
  • 8.3.4. South Korea CT and NG Testing Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product
      • 8.3.4.2.2. By Testing Type
      • 8.3.4.2.3. By Technology
      • 8.3.4.2.4. By End User
  • 8.3.5. Australia CT and NG Testing Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product
      • 8.3.5.2.2. By Testing Type
      • 8.3.5.2.3. By Technology
      • 8.3.5.2.4. By End User

9. Middle East & Africa CT and NG Testing Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
  • 9.2.2. By Testing Type
  • 9.2.3. By Technology
  • 9.2.4. By End User
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia CT and NG Testing Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Testing Type
      • 9.3.1.2.3. By Technology
      • 9.3.1.2.4. By End User
  • 9.3.2. UAE CT and NG Testing Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Testing Type
      • 9.3.2.2.3. By Technology
      • 9.3.2.2.4. By End User
  • 9.3.3. South Africa CT and NG Testing Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Testing Type
      • 9.3.3.2.3. By Technology
      • 9.3.3.2.4. By End User

10. South America CT and NG Testing Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product
  • 10.2.2. By Testing Type
  • 10.2.3. By Technology
  • 10.2.4. By End User
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil CT and NG Testing Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By Testing Type
      • 10.3.1.2.3. By Technology
      • 10.3.1.2.4. By End User
  • 10.3.2. Colombia CT and NG Testing Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By Testing Type
      • 10.3.2.2.3. By Technology
      • 10.3.2.2.4. By End User
  • 10.3.3. Argentina CT and NG Testing Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By Testing Type
      • 10.3.3.2.3. By Technology
      • 10.3.3.2.4. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global CT and NG Testing Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. F. Hoffmann-La Roche Ltd.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Hologic, Inc.
• 15.3. Thermo Fisher Scientific Inc.
• 15.4. Abbott Laboratories Inc.
• 15.5. QIAGEN N.V.
• 15.6. PerkinElmer Inc.
• 15.7. Bio-Rad Laboratories, Inc.
• 15.8. Siemens Healthineers AG
• 15.9. Danaher Corporation
• 15.10. Becton, Dickinson, and Company

16. Strategic Recommendations

17. About Us & Disclaimer